Clinical Studies

Farletuzumab (MORAb-003)

Farletuzumab is an investigational monoclonal antibody that targets folate receptor alpha, a protein that is overexpressed on a number of cancers. It is currently being evaluated in a clinical study for the treatment of platinum-sensitive ovarian cancer.
Read More


Amatuximab (MORAb-009)

Amatuximab is an investigational monoclonal antibody that targets mesothelin, a cell-surface adhesion molecule that is overexpressed on a number of cancers. It is currently being evaluated in a clinical study as a 1st-line therapy for mesothelioma.
Read More


Ontuxizumab (MORAb-004)

MORAb-004 is an investigational monoclonal antibody that targets endosialin, also known as Tumor Endothelial Marker-1 (TEM1), or CD248, a protein that is expressed on tumor-associated pericytes, tumor stromal cells and on some malignant cells. It is currently being evaluated in clinical studies for the treatment of melanoma, chemorefractory metastatic colorectal cancer and sarcoma as well as in pediatric cancers.
Read More


MORAb-022

MORAb-022 is an investigational monoclonal antibody that targets a proinflammatory protein, GM-CSF, associated with autoimmune diseases. A Phase 1 clinical study for the treatment of rheumatoid arthritis has been completed.
Read More


MORAb-066

MORAb-066 is an investigational monoclonal antibody that targets tissue factor. It is currently being evaluated in a Phase 1 clinical study for the treatment of pancreatic, breast, colorectal and non-small cell lung cancer.
Read More

The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.